

## PRESS RELEASE

## EOS imaging Receives China Food and Drug Administration (CFDA) Approval for the EOS® System

*CFDA approval allows EOS imaging to bring low-dose, 2D/3D orthopaedic imaging to the large and growing Chinese market*

**Paris, March 21st, 2016** - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today that the Company has received approval from the China Food and Drug Administration (CFDA) to market the EOS system in China, further expanding the Company's commercial opportunities in the fast growing Asia Pacific market. The EOS system can now be marketed in 51 countries.

The EOS system is in clinical use in several markets in the Asia Pacific region, including Hong Kong, Singapore, Japan, Australia and Vietnam. In addition, an EOS equipment is installed in a Shanghai hospital where it is being used for clinical studies, creating awareness for the EOS technology in China. The CFDA approval will allow the company to develop commercial activity in this major market, which includes more than 1,200 top grade (3A and 3B) hospitals, within an established distribution partnership.

Experience with the EOS system will be shared with Chinese physicians by several French radiologists and orthopedic surgeons during the upcoming Jishuitan Orthopedics Forum in Beijing, April 22-24, 2016. The Forum is a biennial, multi-disciplinary event focused on orthopedics that attracts more than 3,000 attendees from over 1,200 hospitals. This year, the Forum includes special sessions for Chinese-French exchange across multiple areas of orthopedic treatment, including spine, joint articulation, pediatrics and radiology.

Marie Meynadier, CEO of EOS imaging, said, *"CFDA approval is an important milestone that opens a large and growing market opportunity for our Company. It is consistent with our strategy to expand adoption of the EOS system in 3 major regions – North America, Europe-Middle East and Asia-Pacific – to diversify our revenue growth and long-term potential. We are excited to begin commercial activities in China with our local partner, where there is already positive awareness and demand for the EOS system."*

For more information, please visit [www.eos-imaging.com](http://www.eos-imaging.com).

**EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.**

EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI



**Next press release: 2015 Full-year results and 2016 First-quarter sales on April 28, 2016**



## PRESS RELEASE

### **About EOS imaging**

EOS imaging designs, develops, and markets EOS, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2015 revenues of €21.8 million and employs 121 people including an R&D team of 45 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

### **Contacts:**

#### **EOS imaging**

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

#### **NewCap**

Financial communication and investor relations

Pierre Laurent

Ph: +33 (0)1 44 71 94 91

[eosimaging@newcap.fr](mailto:eosimaging@newcap.fr)

#### **The Ruth Group (US)**

Press relations

Joanna Zimmerman

Ph: 646-536-7006

[jzimmerman@theruthgroup.com](mailto:jzimmerman@theruthgroup.com)